Tokyo, Japan

Chie Kudo

USPTO Granted Patents = 3 

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2012-2020

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Chie Kudo: Innovator in Cancer Treatment

Introduction

Chie Kudo is a prominent inventor based in Tokyo, Japan, known for her significant contributions to cancer treatment through innovative research and development. With a total of three patents to her name, she has made strides in the field of oncology, particularly in the development of anticancer agents.

Latest Patents

Kudo's latest patents include groundbreaking inventions aimed at combating cancer. One of her notable patents is focused on anticancer agents or antimetastatic agents using FSTL1 and a combination drug thereof. This invention provides an anti-FSTL1 antibody that recognizes specific epitopes in the human FSTL1 protein, offering a new approach to cancer treatment. Additionally, she has developed a reducer of immunosuppression by tumor cells and an antitumor agent using the same. This invention outlines methods for inhibiting the expression of the FoxP3 gene, reducing immunosuppression, and stimulating tumor immunity, showcasing her commitment to advancing cancer therapies.

Career Highlights

Throughout her career, Chie Kudo has worked with esteemed institutions such as Keio University and Pharma Foods International Co., Ltd. Her work in these organizations has allowed her to collaborate with leading experts in the field, further enhancing her research and innovation capabilities.

Collaborations

Kudo has collaborated with notable colleagues, including Yutaka Kawakami and Masayoshi Toyoura. These partnerships have contributed to her success and the development of her innovative patents.

Conclusion

Chie Kudo's work in cancer treatment exemplifies the impact of innovation in the medical field. Her patents reflect a dedication to improving patient outcomes and advancing therapeutic options for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…